EuroBiotech: More Articles of Note


> Alligator Bioscience entered into a bispecific codevelopment pact with Aptevo Therapeutics. The candidate is based on Alligator's first generation bispecific antibody, ATOR-1016. Release

> E-Therapeutics decided to focus its resources on two immuno-oncology programs after reviewing its operation. The move means e-Therapeutics will try to outlicense other programs. Statement 

> Antabio secured up to up to $8.9 million non-dilutive funding from CARB-X, a public-private antibiotic R&D partnership. The French biotech will use the money to take its treatment for chronic Pseudomonas infections in cystic fibrosis patients up to the end of phase 1. Release


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> The London School of Hygiene and Tropical Medicine named LifeArc as its technology transfer partner. The agreement tasks LifeArc, the organization formerly known as MRC Technology, with maximizing the value of the school’s research. Statement  

> N4 Pharma signed up Bio-Images Drug Delivery to run an early-phase trial of its reformulations of sildenafil, the active ingredient in Pfizer’s Viagra. The trial is designed to tee N4 up to run a larger trial of what it thinks are faster and longer acting erectile dysfunction drugs. Release

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.